Tag: ai in drug discovery market

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Artificial Intelligence (AI) In Drug Discovery Market Forecast: What Market Value Is Expected By 2030?

The market for artificial intelligence in cancer diagnostics has seen rapid expansion in recent years, with its value projected to rise from $0.79 billion in 2025 to $0.96 billion in 2026, reflecting a compound annual growth rate (CAGR) of 20.2%. This historical growth has been driven by factors such as the limited integration of AI into early diagnostic processes, a continued dependence on conventional imaging methods, a global increase in cancer incidence, a growing need for technologies that enable early detection, and the proliferation of diagnostic facilities.

The market for artificial intelligence in cancer diagnostics is projected to experience significant expansion over the coming years, reaching an estimated valuation of $1.97 billion by 2030, driven by a compound annual growth rate of 19.9%. This anticipated growth during the forecast period is fueled by progress in deep learning and machine learning algorithms, the proliferation of AI-enhanced imaging systems, deeper incorporation of predictive analytics into healthcare, increased funding for digital health innovations, and strengthened partnerships between AI developers and medical institutions. Key developments shaping the forecast period encompass the wider uptake of AI-based imaging and diagnostic tools, the integration of predictive analytics into cancer screening processes, the growing utilization of AI for tumor identification and categorization, the expansion of AI-powered monitoring and follow-up systems, and a rise in cooperative efforts between hospitals and AI solution providers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp

Artificial Intelligence (AI) In Drug Discovery Market Growth Factors Supporting Long-Term Expansion

The rising incidence of cancer is anticipated to drive the expansion of artificial intelligence within the cancer diagnostics market in the coming years. Cancer encompasses a range of diseases characterized by abnormal cell growth that can potentially invade or spread to other areas of the body. The incorporation of AI into cancer care is designed to boost efficiency, accuracy, and personalized treatment approaches, ultimately leading to better outcomes for patients. For example, in May 2024, the National Cancer Institute, a U.S.-based government agency, reported that around 2 million new cancer diagnoses are expected in the United States in 2024, with over 611,000 deaths projected. By 2040, the global number of new cancer cases is estimated to reach 29.9 million, while cancer-related deaths are forecast to climb to 15.3 million. Consequently, the growing prevalence of cancer is fueling the advancement of artificial intelligence in the cancer diagnostics market.

#Artificial Intelligence (AI) In Drug Discovery Market Segment Landscape And Growth Potential

The ai in cancer diagnostics market covered in this report is segmented –

1) By Component: Software Solutions, Hardware, Services

2) By Cancer Type: Breast Cancer, Lung Cancer, Brain Tumor, Skin Cancer And Cervical Cancer, Prostate And Colorectal Cancer, Other Cancer Types

3) By Application: Screening And Diagnosis, Tumor Identification, Monitoring

4) By End User: Hospitals, Diagnostic Centers, Medical Research Institutes

Subsegments:

1) By Software Solutions: Machine Learning Software, Deep Learning Software, Image Analysis Software

2) By Hardware: AI-Powered Imaging Systems, Diagnostic Devices

3) By Services: AI Integration Services, Consulting And Training Services, Support And Maintenance Services

Artificial Intelligence (AI) In Drug Discovery Market Industry Trends Shaping Future Revenue Growth

Companies leading the AI in cancer diagnostics market are experiencing notable expansion, fueled by progress in AI-enabled digital pathology systems designed for cancer detection. These systems employ artificial intelligence algorithms to identify cancerous and diagnostic features across various tissue types, delivering precise and timely diagnoses, aiding in case prioritization, and ensuring consistent results. For example, in November 2023, Dedalus, in collaboration with Ibex Medical Analytics, a European health software firm, introduced a comprehensive End-to-End AI-driven digital pathology solution for cancer diagnosis throughout Europe. This innovation is intended to boost accuracy, provide AI-assisted decision support, streamline reporting processes, optimize laboratory workflows, and strengthen diagnostic certainty.

Artificial Intelligence (AI) In Drug Discovery Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the ai in cancer diagnostics market are Microsoft Corporation, IBM Corporation, Verily Life Sciences LLC, Tempus Labs Inc, Guardant Health Inc, Lunit Inc, Paige AI Inc, Viz.ai Inc, Enlitic Inc, Ibex Medical Analytics Ltd, Kheiron Medical Technologies Limited, CureMetrix Inc, CancerIQ Inc, MultiplAI Health Inc, Freenome Holdings Inc, SkinVision B V, Owkin Inc, Imagen Technologies Inc, Cyrcadia Health Inc, Oncora Medical Inc, Xilis Inc

Access The Complete Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Artificial Intelligence (AI) In Drug Discovery Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the artificial intelligence in cancer diagnostics market in 2025. The regions covered in the ai in cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Artificial Intelligence (AI) In Drug Discovery Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28918&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Artificial Intelligence (AI)‑Driven Virtual Nursing Assistants Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The market for virtual nursing assistants powered by artificial intelligence has seen remarkable expansion, projected to increase from $1.76 billion in 2025 to $2.19 billion in 2026, demonstrating a compound annual growth rate of 24.4%. This growth trajectory during the past period has been fueled by several key factors, including a worsening shortage of healthcare personnel, the earlier embrace of telehealth, a rising need for tools that enable patients to manage their own health, the broader integration of digital health solutions, and the increasing accessibility of AI technologies capable of engaging in natural conversation.

The market for AI-powered virtual nursing assistants is poised for substantial expansion, projected to reach $5.19 billion by 2030 with a compound annual growth rate of 24.1%. This anticipated surge is fueled by several key factors, including heightened investment in virtual care infrastructure, a growing need for uninterrupted patient support, the broader integration of AI into clinical processes, a greater emphasis on economical healthcare solutions, and the increasing prevalence of remote patient monitoring. During this forecast period, significant trends will shape the market, such as the wider adoption of virtual nursing tools, increased utilization of AI-driven platforms for patient engagement, deeper integration of remote monitoring technologies, the proliferation of round-the-clock digital care services, and a stronger focus on automating care coordination efforts.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28131&type=smp

Artificial Intelligence (AI)‑Driven Virtual Nursing Assistants Market Opportunity Drivers: What Is Creating New Revenue Potential?

The expansion of the market for AI-powered virtual nursing assistants is anticipated due to the increasing adoption of remote patient monitoring solutions. Remote patient monitoring, which involves utilizing digital tools to gather patient health information outside conventional healthcare environments and relay it to medical professionals for evaluation and ongoing care, is experiencing escalating demand. This surge is attributed to the heightened need for consistent, immediate healthcare oversight beyond the confines of a clinic or hospital. AI-driven virtual nursing assistants contribute significantly to remote patient monitoring by enabling real-time health data tracking, issuing prompt notifications, and facilitating tailored patient care, all while alleviating the workload of healthcare personnel. As an illustration, data from the US Department of Health and Human Services indicated that in August 2025, approximately one million individuals were enrolled in remote patient monitoring programs in 2024, marking a substantial 27% rise compared to the previous year. Consequently, the escalating requirement for remote patient monitoring is acting as a key catalyst for the growth of the AI-driven virtual nursing assistants sector.

Artificial Intelligence (AI)‑Driven Virtual Nursing Assistants Market Segmentation And Category Breakdown

The artificial intelligence (AI)‑driven virtual nursing assistants market covered in this report is segmented –

1) By Component: Software, Services

2) By Technology: Automatic Speech Recognition(ASR), Text-To-Speech(TTS), Text-Based Interface, Natural Language Processing (NLP), Other Technologies

3) By Deployment: Cloud Based, On-Premise, Hybrid

4) By Application: Symptom Checking And Virtual Triage, Appointment Scheduling And Reminders, Medication Management, Medical Information Retrieval, Patient Engagement And Education, Clinical Decision Support, Administrative Support, Remote Monitoring

5) By End User: Hospitals And Clinics, Patients, Healthcare Payers Pharmaceutical And Life Sciences Companies, Other End Users

Subsegments:

1) By Software: Clinical Decision Support, Patient Monitoring And Engagement, Workflow And Care Coordination, Medication Management, Predictive Analytics And Risk Assessment, Communication And Chat Interfaces

2) By Services: Training And Education, Consulting And Advisory, Support And Maintenance, Managed Services, Data Management And Security, Implementation And Integration

Artificial Intelligence (AI)‑Driven Virtual Nursing Assistants Market Innovation Trends Driving Future Development

Within the artificial intelligence powered virtual nursing assistant sector, prominent organizations are innovating with advanced features, including LIDAR-based spatial awareness systems, to facilitate continuous patient oversight, improve safety by identifying potential hazards like falls or abrupt health declines, and bolster virtual nursing frameworks. LIDAR, a sophisticated remote detection method, employs laser light pulses to gauge distances with exceptional precision. As an illustration, Emory Healthcare, a healthcare provider in the United States, initiated an AI-integrated virtual nursing program in March 2025 aimed at elevating patient care standards. This initiative deploys LIDAR technology within patient quarters to track movements and anticipate falls as much as 30 seconds in advance, triggering automated verbal reminders for patients to remain in bed. This technology empowers nurses stationed in a remote command center to manage administrative tasks such as patient admissions, medication administration, patient education sessions, and discharge procedures, thereby allowing on-site nurses to dedicate more attention to direct patient interaction. The system consistently scrutinizes patient information to detect prescient indicators of clinical decline or urgent situations, facilitating prompt notifications to the on-site care staff.

Artificial Intelligence (AI)‑Driven Virtual Nursing Assistants Market Competitive Analysis Of Major Industry Participants

Major companies operating in the artificial intelligence (AI)‑driven virtual nursing assistants market are Microsoft Corporation, HealthTap Inc., Artera Inc., Caregility LLC, Luma Health Inc., Infermedica Sp. z o.o., Memora Health Inc., Buoy Health Inc., Hyro AI Ltd., Care Angel Inc., Sensely Inc., Artisight Inc., K Health Inc., Mediktor International S.L., Corti ApS, AvaSure LLC, Care.AI Inc., Tap Health Inc., GetWellNetwork Inc., Biofourmis Inc.

Access The Complete Artificial Intelligence (AI)‑Driven Virtual Nursing Assistants Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-virtual-nursing-assistants-global-market-report

Artificial Intelligence (AI)‑Driven Virtual Nursing Assistants Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the artificial intelligence (AI)‑driven virtual nursing assistants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)‑driven virtual nursing assistants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Artificial Intelligence (AI) In Drug Discovery Market Growth From $2.93 Billion In 2026 To $7.42 Billion By 2030 At A CAGR Of 26.2%

The market for artificial intelligence in drug discovery has experienced remarkable expansion lately, projected to ascend from $2.33 billion in 2025 to $2.93 billion in 2026, reflecting a formidable compound annual growth rate of 25.9%. This accelerated growth during the preceding period is largely attributable to heightened pharmaceutical research and development expenditures, the escalating intricacy found within drug discovery processes, a greater abundance of both biological and chemical data, the early integration of machine learning techniques within the field of bioinformatics, and a notable increase in cooperative ventures between pharmaceutical companies and technology firms.

The market for artificial intelligence in drug discovery is poised for substantial expansion in the coming years, projecting a rise to $7.42 billion by 2030 with a compound annual growth rate of 26.2%. This upward trajectory is fueled by several key drivers, including the escalating implementation of generative AI methodologies, a burgeoning need for highly personalized treatments, the broader integration of AI into clinical trial planning, increased financial backing for cloud-based research platforms, and a growing endorsement of AI’s role in pharmaceutical development by regulatory bodies. Significant developments anticipated during this period encompass a heightened utilization of AI for pinpointing therapeutic targets, a greater embrace of deep learning techniques for evaluating potential drug molecules, the more widespread incorporation of virtual screening systems, the advancement of AI-powered tools for refining drug candidates, and a concentrated effort to accelerate the overall drug development process.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp

Artificial Intelligence (AI) In Drug Discovery Market Expansion Drivers: What Is Shaping Future Growth?

The increasing requirement for tailored medical treatments is anticipated to be a primary catalyst for the expansion of artificial intelligence (AI) within the drug discovery sector. Personalized medicine, characterized by its focus on disease prevention, diagnosis, and treatment tailored to an individual’s unique genetic makeup, proteomic data, or biological characteristics, is seeing greater acceptance due to the heightened demand for accurate, individualized therapeutic strategies. These approaches aim to boost treatment efficacy while minimizing negative side effects. AI plays a crucial role in facilitating this transition by expediting the pinpointing of molecular targets, refining potential drug compounds, and improving the quality of clinical judgments across the entire drug development process. An illustrative example is the U.S. Food and Drug Administration’s approval of 26 novel personalized therapies in 2023, comprising twenty new molecular entities and six gene- or cell-based treatments, as reported by the Personalized Medicine Coalition in February 2024. Consequently, the escalating need for personalized medicine is a significant factor contributing to the growth of AI in drug discovery.

Artificial Intelligence (AI) In Drug Discovery Market Segment Outlook: Which Categories Are Expanding The Fastest?

The artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning

2) By Drug Type: Small Molecules, Large Molecules

3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics

4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis

3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications

Artificial Intelligence (AI) In Drug Discovery Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Companies at the forefront of the drug discovery sector are channeling significant capital into AI-driven enterprises, aiming to pinpoint and formulate novel therapeutic agents and subsequently make these advanced models accessible to other pharmaceutical entities. Such calculated investments serve to fuel the crucial research and development phases inherent in discovering new medications, a journey often characterized by substantial expenditure and extended timelines. This infusion of capital empowers companies to propel their drug discovery initiatives forward, ultimately facilitating the introduction of innovative treatments into the market. As an illustration, in July of 2023, Nvidia, a prominent American software developer, allocated $50 million to Recursion Pharmaceuticals, a US-based biotechnology firm employing artificial intelligence in its drug discovery endeavors. This financial backing is slated to bolster Recursion’s capacity to expedite the refinement of its AI models underpinning biological and chemical research, leveraging the cloud infrastructure provided by Nvidia.

Artificial Intelligence (AI) In Drug Discovery Market Key Companies And Competitive Benchmarking

Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.

Access The Complete Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Artificial Intelligence (AI) In Drug Discovery Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europewas the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Between 2026 And 2030?

The market size for artificial intelligence (AI)-driven virtual nursing assistants has experienced rapid growth in recent years. This market is expected to expand from $1.76 billion in 2025 to $2.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 24.4%. Key factors contributing to this historical growth include increasing healthcare staff shortages, the early adoption of telehealth services, a growing demand for patient self-management tools, the expansion of digital health platforms, and the availability of conversational AI technologies.

The artificial intelligence (AI)-driven virtual nursing assistants market size is projected to experience substantial expansion in the coming years. By 2030, it is anticipated to reach $5.19 billion, exhibiting a compound annual growth rate (CAGR) of 24.1%. This projected growth is driven by factors such as greater investments in virtual care infrastructure, an increasing need for continuous patient support, the wider deployment of AI-assisted clinical workflows, a growing emphasis on delivering cost-efficient healthcare, and the rising adoption of remote patient monitoring solutions. Key developments anticipated during this period encompass the increased use of virtual nursing support tools, the growing deployment of AI-powered patient engagement platforms, the further integration of remote monitoring capabilities, the expansion of 24/7 digital care assistance, and a strengthened focus on automating care coordination.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28131&type=smp

What Are The Main Drivers Accelerating The Growth Of The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

The increasing need for remote patient monitoring is projected to fuel the expansion of the artificial intelligence (AI)-driven virtual nursing assistants market moving forward. Remote patient monitoring (RPM) involves utilizing digital technologies to gather patients’ health data from outside conventional healthcare environments and transmit it to providers for assessment and care management. The rising demand for remote patient monitoring stems from the heightened necessity for continuous, real-time healthcare oversight beyond traditional clinical settings. Artificial intelligence (AI)-driven virtual nursing assistants in remote patient monitoring assist in tracking patients’ health data in real time, delivering timely alerts, and supporting personalized care, while simultaneously easing the workload for healthcare staff. For instance, in August 2025, as per the US Department of Health and Human Services, a US-based government administration, nearly 1 million enrollees in 2024 received remote patient monitoring, indicating a 27% increase from 2023. Thus, the growing demand for remote patient monitoring is consequently driving the growth of the artificial intelligence (AI)-driven virtual nursing assistants market.

How Does Segment Analysis Break Down The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Structure?

The artificial intelligence (AI)-driven virtual nursing assistants market covered in this report is segmented –

1) By Component: Software, Services

2) By Technology: Automatic Speech Recognition(ASR), Text-To-Speech(TTS), Text-Based Interface, Natural Language Processing (NLP), Other Technologies

3) By Deployment: Cloud Based, On-Premise, Hybrid

4) By Application: Symptom Checking And Virtual Triage, Appointment Scheduling And Reminders, Medication Management, Medical Information Retrieval, Patient Engagement And Education, Clinical Decision Support, Administrative Support, Remote Monitoring

5) By End User: Hospitals And Clinics, Patients, Healthcare Payers Pharmaceutical And Life Sciences Companies, Other End Users

Subsegments:

1) By Software: Clinical Decision Support, Patient Monitoring And Engagement, Workflow And Care Coordination, Medication Management, Predictive Analytics And Risk Assessment, Communication And Chat Interfaces

2) By Services: Training And Education, Consulting And Advisory, Support And Maintenance, Managed Services, Data Management And Security, Implementation And Integration

Which Trends Are Expected To Shape The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

Leading firms within the artificial intelligence (AI)-driven virtual nursing assistants market are innovating with new solutions, including LIDAR-based spatial intelligence systems. These systems facilitate continuous patient oversight, boost safety by proactively identifying dangers like falls or sudden health declines, and bolster virtual nursing frameworks. Specifically, Light detection and ranging (LIDAR) represents sophisticated remote sensing that employs laser light pulses to precisely gauge distances. As an illustration, Emory Healthcare, a US-based healthcare provider, rolled out a virtual nursing program in March 2025, leveraging AI-powered technology to improve patient services. This program integrates Light detection and ranging (LIDAR) technology within patient rooms to track movements and foresee falls up to 30 seconds ahead of time, issuing automated voice prompts to encourage patients to remain in bed. It empowers nurses in a central control center to remotely manage tasks such as admissions documentation, medication administration, patient instruction, and discharge procedures, thus allowing bedside nurses to dedicate more time to hands-on patient care. Furthermore, the system consistently analyzes patient data to pinpoint initial indicators of clinical worsening or emergencies, thereby facilitating prompt notifications to bedside care staff.

Which Industry Players Are Present In The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

Major companies operating in the artificial intelligence (AI)-driven virtual nursing assistants market are Microsoft Corporation, HealthTap Inc., Artera Inc., Caregility LLC, Luma Health Inc., Infermedica Sp. z o.o., Memora Health Inc., Buoy Health Inc., Hyro AI Ltd., Care Angel Inc., Sensely Inc., Artisight Inc., K Health Inc., Mediktor International S.L., Corti ApS, AvaSure LLC, Care.AI Inc., Tap Health Inc., GetWellNetwork Inc., Biofourmis Inc.

Access The Complete Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-virtual-nursing-assistants-global-market-report

Which Region Has The Strongest Presence In The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

North America was the largest region in the artificial intelligence (AI)-driven virtual nursing assistants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven virtual nursing assistants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=28131&type=smp

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market 2026, By The Business Research Company

Intelligent Virtual Assistant Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/intelligent-virtual-assistant-global-market-report

Virtual Assistant Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-assistant-global-market-report

Ai As A Service Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ai-as-a-service-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Size Of The Artificial Intelligence (AI) In Drug Discovery Market In 2026 And How Much Will It Reach By 2030?

The artificial intelligence (AI) in drug discovery market size has experienced significant expansion in recent years. It is forecast to increase from $2.33 billion in 2025 to $2.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 25.9%. The market’s past growth can be attributed to several factors, including escalating pharmaceutical R&D spending, the increasing complexity of drug discovery pipelines, greater availability of biological and chemical datasets, the early adoption of machine learning in bioinformatics, and growing collaboration between pharmaceutical and technology firms.

The artificial intelligence (AI) in drug discovery market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $7.42 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.2%. The expansion during this forecast period is primarily driven by the increasing integration of generative AI models, a rising need for precision therapeutics, the broadening of AI-enabled clinical trial designs, expanding investments in cloud-based discovery platforms, and the regulatory acceptance of AI-assisted drug development. Noteworthy trends expected in the forecast period include a greater utilization of AI-driven target identification, increased adoption of deep learning for molecule screening, the growing integration of virtual drug screening platforms, the proliferation of AI-based lead optimization tools, and an enhanced focus on reducing drug development timelines.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3411&type=smp

Which Core Factors Are Supporting The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?

The increasing need for personalized medicine is anticipated to fuel the expansion of artificial intelligence (AI) within the drug discovery market in the future. Personalized medicine represents a focused strategy for preventing, diagnosing, and treating diseases, utilizing an individual’s unique genetic, proteomic, or biological makeup to inform medical choices. The greater uptake of personalized medicine stems from the growing requirement for accurate, tailored therapies that enhance treatment outcomes and minimize side effects. AI facilitates this transition by speeding up the discovery of molecular targets, refining drug compounds, and improving clinical judgment across the entire development process. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based advocacy and research body, indicated that the U.S. FDA sanctioned 26 novel personalized treatments in 2023, comprising 20 new molecular entities and 6 gene- or cell-based therapies. Consequently, the expanding demand for personalized medicine is stimulating the advancement of artificial intelligence (AI) in the drug discovery market.

How Does Segment Analysis Break Down The Artificial Intelligence (AI) In Drug Discovery Market Structure?

The artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning

2) By Drug Type: Small Molecules, Large Molecules

3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics

4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis

3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications

What Trends Are Affecting The Artificial Intelligence (AI) In Drug Discovery Market Dynamics?

Leading corporations are allocating capital to firms leveraging artificial intelligence (AI) within the drug discovery sector, aiming to pinpoint and develop novel treatments and provide these methodologies to other pharmaceutical manufacturers. Such calculated investments offer financial support for the research and development phases of novel pharmaceuticals, an endeavor often characterized by high expenses and extended timelines. This financial backing enables companies to accelerate their drug discovery initiatives and introduce innovative therapies to the market. A notable example occurred in July 2023, when Nvidia, a US-based software firm, committed $50 million to Recursion Pharmaceuticals, a US-based biotechnology enterprise utilizing artificial intelligence (AI) for drug discovery. This capital injection is intended to assist Recursion in speeding up the creation of its AI foundation models for biological and chemical applications, facilitated by leveraging Nvidia’s cloud infrastructure.

Who Are The Companies Shaping The Artificial Intelligence (AI) In Drug Discovery Market Landscape?

Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.

Access The Complete Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Which Region Stands As The Largest Contributor To The Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Artificial Intelligence (AI) In Drug Discovery Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=3411&type=smp

Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company

Generative Artificial Intelligence Ai In Drug Discovery Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Artificial Intelligence Ai In Biopharmaceuticals Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

Artificial Intelligence Ai In Predictive Toxicology Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-predictive-toxicology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Artificial Intelligence (AI) In Drug Discovery Market Progress Between 2026 And 2030?

The artificial intelligence (AI) in drug discovery market has seen substantial expansion in recent years. Its value is projected to grow from $2.33 billion in 2025 to $2.93 billion in 2026, at a compound annual growth rate (CAGR) of 25.9%. Historically, this growth has been driven by increasing pharmaceutical R&D spending, the growing complexity of drug discovery pipelines, rising availability of biological and chemical datasets, early adoption of machine learning in bioinformatics, and increasing collaboration between pharma and tech firms.

The artificial intelligence (AI) in drug discovery market size is anticipated to experience significant growth in the coming years. It is projected to expand to $7.42 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.2%. This growth during the forecast period is driven by factors such as the increasing adoption of generative AI models, a rising demand for precision therapeutics, the expansion of AI-enabled clinical trial design, growing investments in cloud-based discovery platforms, and regulatory acceptance of AI-assisted drug development. Noteworthy trends in the forecast period include the increasing use of AI-driven target identification, a rising adoption of deep learning for molecule screening, the growing integration of virtual drug screening platforms, the expansion of AI-based lead optimization tools, and an enhanced focus on reducing drug development timelines.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?

The increasing need for personalized medicine is projected to drive the expansion of artificial intelligence (AI) within the drug discovery market. Personalized medicine involves a focused strategy for preventing, diagnosing, and treating diseases, utilizing an individual’s genetic, proteomic, or biological information to inform medical choices. The increasing uptake of personalized medicine is fueled by the growing requirement for exact, patient-tailored treatments that enhance therapeutic efficacy and minimize negative reactions. AI facilitates this transition by speeding up the discovery of molecular targets, refining potential drugs, and improving clinical judgments across the entire development process. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy and research entity, reported that the U.S. FDA cleared 26 novel personalized therapies in 2023, comprising 20 new molecular entities and 6 therapies based on genes or cells. Consequently, the escalating demand for personalized medicine is propelling the advancement of artificial intelligence (AI) in the drug discovery market.

How Are Different Segments Classified In The Artificial Intelligence (AI) In Drug Discovery Market Segment Analysis?

The artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning

2) By Drug Type: Small Molecules, Large Molecules

3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics

4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis

3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications

Which Trends Are Shaping The Artificial Intelligence (AI) In Drug Discovery Market?

Leading corporations are allocating capital to firms involved in artificial intelligence (AI) within the drug discovery sector, aiming to pinpoint and develop novel treatments and subsequently provide these methodologies to other pharmaceutical manufacturers. Such strategic financial backing is crucial for supporting the research and development of novel pharmaceuticals, an endeavor known for being both expensive and protracted. This capital infusion enables companies to accelerate their drug discovery initiatives and introduce innovative therapies to the market. An example of this trend is Nvidia, a software firm based in the US, which in July 2023 committed $50 million to Recursion Pharmaceuticals, a US-based biotechnology company that leverages artificial intelligence (AI) for drug discovery purposes. This particular investment is intended to empower Recursion in expediting the creation of its foundational AI models for biological and chemical applications, utilizing Nvidia’s suite of cloud services.

Who Are The Companies Driving Activity In The Artificial Intelligence (AI) In Drug Discovery Market?

Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.

Get The Full Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Which Region Accounts For The Largest Portion Of The Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Artificial Intelligence (AI) In Drug Discovery Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company

Artificial Intelligence Ai In Predictive Toxicology Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-predictive-toxicology-global-market-report

Generative Artificial Intelligence Ai In Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Artificial Intelligence (AI) In Drug Discovery Market Progress Between 2026 And 2030?

The artificial intelligence (AI) in drug discovery market has seen substantial expansion in recent years. Its value is projected to grow from $2.33 billion in 2025 to $2.93 billion in 2026, at a compound annual growth rate (CAGR) of 25.9%. Historically, this growth has been driven by increasing pharmaceutical R&D spending, the growing complexity of drug discovery pipelines, rising availability of biological and chemical datasets, early adoption of machine learning in bioinformatics, and increasing collaboration between pharma and tech firms.

The artificial intelligence (AI) in drug discovery market size is anticipated to experience significant growth in the coming years. It is projected to expand to $7.42 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.2%. This growth during the forecast period is driven by factors such as the increasing adoption of generative AI models, a rising demand for precision therapeutics, the expansion of AI-enabled clinical trial design, growing investments in cloud-based discovery platforms, and regulatory acceptance of AI-assisted drug development. Noteworthy trends in the forecast period include the increasing use of AI-driven target identification, a rising adoption of deep learning for molecule screening, the growing integration of virtual drug screening platforms, the expansion of AI-based lead optimization tools, and an enhanced focus on reducing drug development timelines.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?

The increasing need for personalized medicine is projected to drive the expansion of artificial intelligence (AI) within the drug discovery market. Personalized medicine involves a focused strategy for preventing, diagnosing, and treating diseases, utilizing an individual’s genetic, proteomic, or biological information to inform medical choices. The increasing uptake of personalized medicine is fueled by the growing requirement for exact, patient-tailored treatments that enhance therapeutic efficacy and minimize negative reactions. AI facilitates this transition by speeding up the discovery of molecular targets, refining potential drugs, and improving clinical judgments across the entire development process. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy and research entity, reported that the U.S. FDA cleared 26 novel personalized therapies in 2023, comprising 20 new molecular entities and 6 therapies based on genes or cells. Consequently, the escalating demand for personalized medicine is propelling the advancement of artificial intelligence (AI) in the drug discovery market.

How Are Different Segments Classified In The Artificial Intelligence (AI) In Drug Discovery Market Segment Analysis?

The artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning

2) By Drug Type: Small Molecules, Large Molecules

3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics

4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis

3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications

Which Trends Are Shaping The Artificial Intelligence (AI) In Drug Discovery Market?

Leading corporations are allocating capital to firms involved in artificial intelligence (AI) within the drug discovery sector, aiming to pinpoint and develop novel treatments and subsequently provide these methodologies to other pharmaceutical manufacturers. Such strategic financial backing is crucial for supporting the research and development of novel pharmaceuticals, an endeavor known for being both expensive and protracted. This capital infusion enables companies to accelerate their drug discovery initiatives and introduce innovative therapies to the market. An example of this trend is Nvidia, a software firm based in the US, which in July 2023 committed $50 million to Recursion Pharmaceuticals, a US-based biotechnology company that leverages artificial intelligence (AI) for drug discovery purposes. This particular investment is intended to empower Recursion in expediting the creation of its foundational AI models for biological and chemical applications, utilizing Nvidia’s suite of cloud services.

Who Are The Companies Driving Activity In The Artificial Intelligence (AI) In Drug Discovery Market?

Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.

Get The Full Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Which Region Accounts For The Largest Portion Of The Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Artificial Intelligence (AI) In Drug Discovery Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company

Artificial Intelligence Ai In Predictive Toxicology Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-predictive-toxicology-global-market-report

Generative Artificial Intelligence Ai In Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Artificial Intelligence (AI) In Drug Discovery Market Progress Between 2026 And 2030?

The artificial intelligence (AI) in drug discovery market has seen substantial expansion in recent years. Its value is projected to grow from $2.33 billion in 2025 to $2.93 billion in 2026, at a compound annual growth rate (CAGR) of 25.9%. Historically, this growth has been driven by increasing pharmaceutical R&D spending, the growing complexity of drug discovery pipelines, rising availability of biological and chemical datasets, early adoption of machine learning in bioinformatics, and increasing collaboration between pharma and tech firms.

The artificial intelligence (AI) in drug discovery market size is anticipated to experience significant growth in the coming years. It is projected to expand to $7.42 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.2%. This growth during the forecast period is driven by factors such as the increasing adoption of generative AI models, a rising demand for precision therapeutics, the expansion of AI-enabled clinical trial design, growing investments in cloud-based discovery platforms, and regulatory acceptance of AI-assisted drug development. Noteworthy trends in the forecast period include the increasing use of AI-driven target identification, a rising adoption of deep learning for molecule screening, the growing integration of virtual drug screening platforms, the expansion of AI-based lead optimization tools, and an enhanced focus on reducing drug development timelines.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?

The increasing need for personalized medicine is projected to drive the expansion of artificial intelligence (AI) within the drug discovery market. Personalized medicine involves a focused strategy for preventing, diagnosing, and treating diseases, utilizing an individual’s genetic, proteomic, or biological information to inform medical choices. The increasing uptake of personalized medicine is fueled by the growing requirement for exact, patient-tailored treatments that enhance therapeutic efficacy and minimize negative reactions. AI facilitates this transition by speeding up the discovery of molecular targets, refining potential drugs, and improving clinical judgments across the entire development process. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy and research entity, reported that the U.S. FDA cleared 26 novel personalized therapies in 2023, comprising 20 new molecular entities and 6 therapies based on genes or cells. Consequently, the escalating demand for personalized medicine is propelling the advancement of artificial intelligence (AI) in the drug discovery market.

How Are Different Segments Classified In The Artificial Intelligence (AI) In Drug Discovery Market Segment Analysis?

The artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning

2) By Drug Type: Small Molecules, Large Molecules

3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics

4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis

3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications

Which Trends Are Shaping The Artificial Intelligence (AI) In Drug Discovery Market?

Leading corporations are allocating capital to firms involved in artificial intelligence (AI) within the drug discovery sector, aiming to pinpoint and develop novel treatments and subsequently provide these methodologies to other pharmaceutical manufacturers. Such strategic financial backing is crucial for supporting the research and development of novel pharmaceuticals, an endeavor known for being both expensive and protracted. This capital infusion enables companies to accelerate their drug discovery initiatives and introduce innovative therapies to the market. An example of this trend is Nvidia, a software firm based in the US, which in July 2023 committed $50 million to Recursion Pharmaceuticals, a US-based biotechnology company that leverages artificial intelligence (AI) for drug discovery purposes. This particular investment is intended to empower Recursion in expediting the creation of its foundational AI models for biological and chemical applications, utilizing Nvidia’s suite of cloud services.

Who Are The Companies Driving Activity In The Artificial Intelligence (AI) In Drug Discovery Market?

Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.

Get The Full Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Which Region Accounts For The Largest Portion Of The Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Artificial Intelligence (AI) In Drug Discovery Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company

Artificial Intelligence Ai In Predictive Toxicology Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-predictive-toxicology-global-market-report

Generative Artificial Intelligence Ai In Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Be By 2030 Compared To Its 2026 Market Size?

The artificial intelligence (AI)-driven virtual nursing assistants market has experienced significant expansion in recent years. It is projected to increase from $1.76 billion in 2025 to $2.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 24.4%. The historical development of this market is attributable to various factors including increasing healthcare staff shortages, the early adoption of telehealth services, a growing demand for patient self-management tools, the expansion of digital health platforms, and the availability of conversational AI technologies.

The market for artificial intelligence (AI)-driven virtual nursing assistants is poised for significant expansion in the foreseeable future, with its valuation expected to climb to $5.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 24.1%. This projected growth is driven by increasing investments in virtual care infrastructure, a rising need for ongoing patient support, the expansion of AI-assisted clinical workflows, a heightened emphasis on cost-efficient healthcare delivery, and the growing adoption of remote patient monitoring solutions. Major developments anticipated in this period include the wider embrace of virtual nursing support tools, an increase in the use of AI-powered platforms for patient engagement, the expanding integration of remote monitoring capabilities, the proliferation of 24/7 digital care assistance, and a stronger focus on automating care coordination.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-virtual-nursing-assistants-global-market-report

Which Drivers Are Supporting The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Growth?

The increasing need for remote patient monitoring is anticipated to drive the expansion of the artificial intelligence (AI)-driven virtual nursing assistants market in the future. Remote patient monitoring (RPM) involves leveraging digital tools to gather patient health information from non-traditional medical environments and relay it to healthcare professionals for evaluation and management. This rising demand for remote patient monitoring stems from the increasing requirement for ongoing, real-time health supervision beyond conventional clinic environments. Within remote patient monitoring, artificial intelligence (AI)-driven virtual nursing assistants facilitate real-time tracking of patient health data, issue prompt alerts, and aid in personalized care, concurrently lessening the workload for healthcare personnel. For example, data from August 2025 by the US Department of Health and Human Services, a US-based government administration, showed that close to 1 million enrollees utilized remote patient monitoring in 2024, marking a 27% rise compared to 2023. Consequently, the escalating demand for remote patient monitoring is fueling the expansion of the artificial intelligence (AI)-driven virtual nursing assistants market.

How Is The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Categorized Across Its Segment Groups?

The artificial intelligence (AI)-driven virtual nursing assistants market covered in this report is segmented –

1) By Component: Software, Services

2) By Technology: Automatic Speech Recognition(ASR), Text-To-Speech(TTS), Text-Based Interface, Natural Language Processing (NLP), Other Technologies

3) By Deployment: Cloud Based, On-Premise, Hybrid

4) By Application: Symptom Checking And Virtual Triage, Appointment Scheduling And Reminders, Medication Management, Medical Information Retrieval, Patient Engagement And Education, Clinical Decision Support, Administrative Support, Remote Monitoring

5) By End User: Hospitals And Clinics, Patients, Healthcare Payers Pharmaceutical And Life Sciences Companies, Other End Users

Subsegments:

1) By Software: Clinical Decision Support, Patient Monitoring And Engagement, Workflow And Care Coordination, Medication Management, Predictive Analytics And Risk Assessment, Communication And Chat Interfaces

2) By Services: Training And Education, Consulting And Advisory, Support And Maintenance, Managed Services, Data Management And Security, Implementation And Integration

Which Trends Are Expected To Impact The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

Leading companies in the artificial intelligence (AI)-driven virtual nursing assistants market are advancing new technologies, such as LIDAR-based spatial intelligence, to facilitate real-time patient monitoring, bolster safety through the early detection of risks like falls or sudden health declines, and support virtual nursing models. Light detection and ranging (LIDAR) is an sophisticated remote sensing method that employs laser light pulses to precisely measure distances. As an illustration, in March 2025, Emory Healthcare, a US-based healthcare system, initiated a virtual nursing program utilizing AI-driven technology to improve patient care. This program integrates Light detection and ranging (LIDAR) technology in patient rooms to observe movements and predict falls up to 30 seconds before they occur, using automated voice alerts to advise patients to remain in bed. It allows nurses located in a central control room to manage admission paperwork, medication administration, patient education, and discharge processes remotely, thereby enabling bedside nurses to dedicate more time to direct patient care. The system continuously analyzes patient data to identify initial signs of clinical deterioration or emergencies, ensuring timely alerts reach bedside care teams.

Which Firms Are Influencing Competition In The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

Major companies operating in the artificial intelligence (AI)-driven virtual nursing assistants market are Microsoft Corporation, HealthTap Inc., Artera Inc., Caregility LLC, Luma Health Inc., Infermedica Sp. z o.o., Memora Health Inc., Buoy Health Inc., Hyro AI Ltd., Care Angel Inc., Sensely Inc., Artisight Inc., K Health Inc., Mediktor International S.L., Corti ApS, AvaSure LLC, Care.AI Inc., Tap Health Inc., GetWellNetwork Inc., Biofourmis Inc.

Get The Full Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-virtual-nursing-assistants-global-market-report

Which Region Has The Greatest Market Share In The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

North America was the largest region in the artificial intelligence (AI)-driven virtual nursing assistants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven virtual nursing assistants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-virtual-nursing-assistants-global-market-report

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market 2026, By The Business Research Company

Intelligent virtual assistants software market report 2026

https://www.thebusinessresearchcompany.com/report/intelligent-virtual-assistants-software-global-market-report

intelligent virtual assistant global market report

https://www.thebusinessresearchcompany.com/report/intelligent-virtual-assistant-global-market-report

virtual assistant global market report

https://www.thebusinessresearchcompany.com/report/virtual-assistant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Over The 2026–2030 Period?

The artificial intelligence (AI)-driven virtual nursing assistants market has experienced substantial growth in recent years. It is anticipated to expand from $1.76 billion in 2025 to $2.19 billion in 2026, at a compound annual growth rate (CAGR) of 24.4%. This historical growth can be attributed to several factors, including increasing healthcare staff shortages, the early adoption of telehealth services, a growing demand for patient self-management tools, the expansion of digital health platforms, and the availability of conversational AI technologies.

The artificial intelligence (AI)-driven virtual nursing assistants market is anticipated to show significant expansion in the upcoming years, with its size expected to reach $5.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 24.1%. This projected growth throughout the forecast period stems from factors such as increasing investments in virtual care infrastructure, a rising demand for continuous patient support, the expansion of AI-assisted clinical workflows, a growing focus on cost-efficient healthcare delivery, and the increasing adoption of remote patient monitoring solutions. Additionally, major trends during this period include the increasing adoption of virtual nursing support tools, the rising use of AI-powered patient engagement platforms, the growing integration of remote monitoring capabilities, the expansion of 24/7 digital care assistance, and an enhanced focus on care coordination automation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28131&type=smp

Which Economic Or Industry Drivers Are Impacting The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

The increasing requirement for remote patient monitoring is anticipated to propel the expansion of the artificial intelligence (AI)-driven virtual nursing assistants market going forward. Remote patient monitoring (RPM) involves the application of digital technologies to collect patients’ health data from outside conventional healthcare environments and transmit it to healthcare providers for assessment and care management. The rising demand for remote patient monitoring stems from the escalating need for continuous, real-time healthcare management beyond traditional clinical settings. Artificial intelligence (AI)-driven virtual nursing assistants, in the context of remote patient monitoring, aid in tracking patients’ health data in real time, delivering timely alerts, and supporting personalized care, thereby reducing the burden on healthcare staff. For instance, in August 2025, data from the US Department of Health and Human Services, a US-based government administration, revealed that in 2024, nearly 1 million enrollees received remote patient monitoring, marking a 27% increase compared to 2023. Consequently, the growing demand for remote patient monitoring is driving the growth of the artificial intelligence (AI)-driven virtual nursing assistants market.

How Is The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Segmented Across Key Categories?

The artificial intelligence (AI)-driven virtual nursing assistants market covered in this report is segmented –

1) By Component: Software, Services

2) By Technology: Automatic Speech Recognition(ASR), Text-To-Speech(TTS), Text-Based Interface, Natural Language Processing (NLP), Other Technologies

3) By Deployment: Cloud Based, On-Premise, Hybrid

4) By Application: Symptom Checking And Virtual Triage, Appointment Scheduling And Reminders, Medication Management, Medical Information Retrieval, Patient Engagement And Education, Clinical Decision Support, Administrative Support, Remote Monitoring

5) By End User: Hospitals And Clinics, Patients, Healthcare Payers Pharmaceutical And Life Sciences Companies, Other End Users

Subsegments:

1) By Software: Clinical Decision Support, Patient Monitoring And Engagement, Workflow And Care Coordination, Medication Management, Predictive Analytics And Risk Assessment, Communication And Chat Interfaces

2) By Services: Training And Education, Consulting And Advisory, Support And Maintenance, Managed Services, Data Management And Security, Implementation And Integration

What Trends Are Affecting The Expansion Of The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

Major companies operating in the artificial intelligence (AI)-driven virtual nursing assistants market are developing new technologies, such as LIDAR-based spatial intelligence, to facilitate real-time patient monitoring, improve safety through early detection of risks like falls or sudden health deterioration, and support virtual nursing models. Light detection and ranging (LIDAR) is an advanced remote sensing technology that uses laser light pulses to measure distances with exceptional accuracy. For instance, in March 2025, Emory Healthcare, a US-based healthcare system, launched a virtual nursing initiative employing AI-driven technology to enhance patient care. This initiative utilizes Llght detection and ranging (LIDAR) technology in patient rooms to track movements and detect falls up to 30 seconds before they happen, complemented by automated voice alerts that prompt patients to stay in bed. It enables nurses located in a central control room to remotely conduct admissions paperwork, manage medications, provide patient education, and oversee discharge activities, thereby allowing bedside nurses to dedicate more attention to direct patient care. Furthermore, it continuously analyzes patient data to identify early indicators of clinical decline or emergencies, facilitating timely alerts to bedside care teams.

Who Are The Dominant Players Shaping The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Landscape?

Major companies operating in the artificial intelligence (AI)-driven virtual nursing assistants market are Microsoft Corporation, HealthTap Inc., Artera Inc., Caregility LLC, Luma Health Inc., Infermedica Sp. z o.o., Memora Health Inc., Buoy Health Inc., Hyro AI Ltd., Care Angel Inc., Sensely Inc., Artisight Inc., K Health Inc., Mediktor International S.L., Corti ApS, AvaSure LLC, Care.AI Inc., Tap Health Inc., GetWellNetwork Inc., Biofourmis Inc.

Read the full artificial intelligence (ai)-driven virtual nursing assistants market report here:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-virtual-nursing-assistants-global-market-report

What Are The Top-Performing Regions Within The Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market?

North America was the largest region in the artificial intelligence (AI)-driven virtual nursing assistants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven virtual nursing assistants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28131&type=smp

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Virtual Nursing Assistants Market 2026, By The Business Research Company

Intelligent Virtual Assistant Global Market Report

https://www.thebusinessresearchcompany.com/report/intelligent-virtual-assistant-global-market-report

Virtual Assistant Global Market Report

https://www.thebusinessresearchcompany.com/report/virtual-assistant-global-market-report

Ai As A Service Global Market Report

https://www.thebusinessresearchcompany.com/report/ai-as-a-service-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model